

RECEIVED

MAY 22 2001

In Re Application of: REIMANN et al.

Application No.: 09/241,595

Filed: February 2, 1999

For: DELIVERY OF IMMUNOGENIC MOLECULES VIA HBSAG PARTICLES

Art Unit: 1632

Examiner: A Beckerleg

Washington, D.C.

Atty.'s Docket: REIMANN=1

Date: May 21, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

BY HANDCARRY

TECH CENTER 1600/2900

#12

5-23-01

P.2

Sir:

Transmitted herewith is a ☐ Amendment ☒ SECOND SUPPLEMENTAL RESPONSE

in the above-identified application.

☒ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.☒ No additional fee is required.☐ The fee has been calculated as shown below:

	(Col.)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID	PRESENT EXTRA EQUALS
TOTAL	* 30	MINUS	** 30	0
INDEP.	* 4	MINUS	*** 4	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 9	\$		x 18	\$
x 40	\$		x 80	\$
+ 135	\$		+ 270	\$
ADDITIONAL FEE TOTAL			TOTAL	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

☒ Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

☐ It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

☐ First - \$ 55.00☐ Second - \$ 195.00☐ Third - \$ 445.00☐ Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

☐ First - \$ 110.00☐ Second - \$ 390.00☐ Third - \$ 890.00☐ Fourth - \$ 1390.00

Month After Time Period Set

☐ Less fees (\$) already paid for ___ month(s) extension of time on _____.☐ Please charge my Deposit Account No. 02-4035 in the amount of \$_____.☐ Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$_____.☐ A check in the amount of \$_____ is attached (check no.).☒ The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Allen C. Yun
Registration No. 37,971Facsimile: (202) 737-3528
Telephone: (202) 628-5197

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: REIMANN=1

In re Application of:)	Examiner: A. Beckerleg
Jorg REIMANN et al)	Art Unit: 1632
Appln. No.: 09/241,595)	Washington, D.C.
Confirmation No.: 8928)	
Filed: February 2, 1999)	May 21, 2001
For: DELIVERY OF IMMUNOGENIC)	
MOLECULES VIA HbsAg)	BY HANDCARRY
PARTICLES)	

09/241,595
05/21/2001
05/21/2001

SECOND SUPPLEMENTAL RESPONSE

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:


Supplemental to the response filed March 20, 2001, and May 3, 2001, on which applicants continue to primarily rely, attached hereto is a copy of an article entitled "New and Improved Vaccines Against Hepatitis B. I. Recombinant-Derived Hepatitis B Vaccine" by Ronald W. Ellis cited in the response filed March 20, 2001, and not included with copies of articles in the supplemental response filed May 3, 2001.

Favorable consideration and allowance are earnestly urged.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


Allen C. Yun

Registration No. 37,971

ACY:pr

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

F:\C\ohn\Reimann1\Pto\2nd supplemental response.wpd